Ovarian cancer represent approximately 25% of gynecologic malignancies but accounts for over 50% of gynecologic cancer deaths. Eighty-five to ninety percent of ovarian cancers are to the epithelial cell type. The overall theme of this Program Project (renewal of CA 52477) is to improve the understanding of the biology of epithelial ovarian cancer, improve the therapy of the disease, and improve the quality of life of the patients. This theme will be achieved through completion of four Projects with the support of four cores in a Program Project that has been designed to maximize existing collaborations and to develop new collaborations. The effective multidisciplinary collaboration on a single theme will allow shared resources and will stimulate the development and integration of ideas from different areas of expertise in such a way that the whole will be greater than the sum of the parts.
The specific aim of this Program Project in epithelial ovarian cancer is the confirmation of the following hypotheses: 1) Intensification of therapy (surgical and chemotherapeutic) can improve survival in ovarian cancer. 2) Improvement in salvage therapy can be achieved and this will lead to improved initial therapy. 3) Pain is a significant factor in determining quality of life in ovarian cancer patients and better understanding of pain syndromes will allow logical and effective interventions to relieve pain and improve quality of life. 4) Recognition of pain syndromes may allow earlier detection of initial and recurrent disease. 5) Radiolabeled monoclonal antibodies can, using body scans as well as novel hand-held devices, detect small residual ovarian cancer. 6) When tumors can be localized by radiolabeled antibodies, therapeutic isotopes can be used with these antibodies to treat minimal residual ovarian cancer. 7) Analysis of antigenic and molecular markers for epithelial ovarian cancer can improve our understanding of the development of ovarian cancer. 8) Further analyses of monoclonal antibodies will allow for the development of better antibodies or modification of existing antibodies to diagnose and treat ovarian cancer. The superb resources and active support of Memorial Sloan-Kettering Cancer Center provide an ideal setting for this Program Project. The combined expertise of the investigators involved provides ample experience and knowledge to carry out this Project successfully.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
3P01CA052477-07S1
Application #
2858498
Study Section
Special Emphasis Panel (SRC (R1))
Program Officer
Bronzert, Diane
Project Start
1991-04-15
Project End
1998-09-29
Budget Start
1997-02-01
Budget End
1998-09-29
Support Year
7
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Grisham, Rachel N; Sylvester, Brooke E; Won, Helen et al. (2015) Extreme Outlier Analysis Identifies Occult Mitogen-Activated Protein Kinase Pathway Mutations in Patients With Low-Grade Serous Ovarian Cancer. J Clin Oncol 33:4099-105
Rao, Thapi D; Tian, Huasong; Ma, Xun et al. (2015) Expression of the Carboxy-Terminal Portion of MUC16/CA125 Induces Transformation and Tumor Invasion. PLoS One 10:e0126633
Tew, William P; Colombo, Nicoletta; Ray-Coquard, Isabelle et al. (2014) Intravenous aflibercept in patients with platinum-resistant, advanced ovarian cancer: results of a randomized, double-blind, phase 2, parallel-arm study. Cancer 120:335-43
Tsuji, Takemasa; Sabbatini, Paul; Jungbluth, Achim A et al. (2013) Effect of Montanide and poly-ICLC adjuvant on human self/tumor antigen-specific CD4+ T cells in phase I overlapping long peptide vaccine trial. Cancer Immunol Res 1:340-50
Hyman, David M; Zhou, Qin; Iasonos, Alexia et al. (2012) Improved survival for BRCA2-associated serous ovarian cancer compared with both BRCA-negative and BRCA1-associated serous ovarian cancer. Cancer 118:3703-9
Marchini, Sergio; Poynor, Elizabeth; Barakat, Richard R et al. (2012) The zinc finger gene ZIC2 has features of an oncogene and its overexpression correlates strongly with the clinical course of epithelial ovarian cancer. Clin Cancer Res 18:4313-24
Iasonos, Alexia; Sabbatini, Paul; Spriggs, David R et al. (2012) Identifying clinical improvement in consolidation single-arm phase 2 trials in patients with ovarian cancer in second or greater clinical remission. Int J Gynecol Cancer 22:63-9
Soslow, Robert A; Han, Guangming; Park, Kay J et al. (2012) Morphologic patterns associated with BRCA1 and BRCA2 genotype in ovarian carcinoma. Mod Pathol 25:625-36
Blixt, Ola; Lavrova, Olga I; Mazurov, Dmitriy V et al. (2012) Analysis of Tn antigenicity with a panel of new IgM and IgG1 monoclonal antibodies raised against leukemic cells. Glycobiology 22:529-42
Gardner, Ginger J; Baser, Raymond E; Brady, Mark F et al. (2012) CA125 regression in ovarian cancer patients treated with intravenous versus intraperitoneal platinum-based chemotherapy: a gynecologic oncology group study. Gynecol Oncol 124:216-20

Showing the most recent 10 out of 109 publications